Radium-223 dichloride: A new paradigm in the treatment of prostate cancer

Expert Review of Anticancer Therapy

Volumn 15, Issue 3, 2015, Pages 339-348

  Herranz, Urbano Anido ^a   Calvo, Ovidio Fernández ^b   Afonso, Francisco Javier Afonso ^c   De Llano, Sofía Rodríguez Martínez ^d   Quintela, Martín Lázaro ^e   Mateos, Luis León ^a   Estévez, Sergio Vázquez ^f   Aparicio, Luis Miguel Antón ^g  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b Instituto de Investigación Biomédica Ourense Vigo Pontevedra   (Spain)

^c Universidad de La Coruña   (Spain)

^d Centro Oncologico de Galicia   (Spain)

^e UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^f Hospital Universitario Lucus Augusti de Lugo   (Spain)

^g HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

alpha emitters; bone metastases; prostate cancer; radiopharmaceuticals; radium 223

Indexed keywords

ABIRATERONE; ALKALINE PHOSPHATASE; CABAZITAXEL; ENZALUTAMIDE; FLUORINE 18; PLACEBO; PROSTATE SPECIFIC ANTIGEN; RADIUM CHLORIDE RA 223; ANTINEOPLASTIC AGENT; RADIOISOTOPE; RADIUM;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; APLASTIC ANEMIA; ASTHENIA; BONE CANCER; BONE MARROW SUPPRESSION; BONE PAIN; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CASTRATION RESISTANT PROSTATE CANCER; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME BLOOD LEVEL; FATIGUE; FEBRILE NEUTROPENIA; HEADACHE; HOT FLUSH; HUMAN; HYPERTENSION; JAW OSTEONECROSIS; LEUKOPENIA; MULTICENTER STUDY (TOPIC); MYELODYSPLASTIC SYNDROME; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RADIATION DOSE; RADIATION PROTECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT WITHDRAWAL; VOMITING; ANIMAL; BONE TUMOR; MALE; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SECONDARY; SURVIVAL RATE;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOISOTOPES; RADIUM; SURVIVAL RATE;

EID: 84923925529     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2015.999045     Document Type: Review

References (49)

1. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80: 1588-94
2. Jimenez-Andrade JM, Mantyh WG, Bloom AP, et al. Bone cancer pain. Ann N Y Acad Sci 2010; 1198: 173-81
3. Saylor PJ, Smith MR. Bone health and prostate cancer. Prostate Cancer Prostatic Dis 2010; 13: 20-7
4. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12: 6243s-9s
5. Adami S. Bisphosphonates in prostate carcinoma. Cancer 1997; 80(8 Suppl): 1674-9
6. Silberstein EB. Systemic radiopharmaceutical therapy of painful osteoblastic metastases. Semin Radiat Oncol 2000; 10: 240-9
7. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27: 1564-71
8. Lutz S, Berk L, Chang E, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011; 79: 965-76
9. Robinson RG, Preston DF, Schiefelbein M, Baxter KG. Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 1995; 274: 420-4
10. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998; 16: 1574-81
11. Maxon HR III, Schroder LE, Hertzberg VS, et al. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J Nucl Med 1991; 32: 1877-81
12. Atkins HL. Overview of nuclides for bone pain palliation. Appl Radiat Isot 1998; 49: 277-83
13. Srivastava SC, Atkins HL, Krishnamurthy GT, et al. Treatment of metastatic bone pain with tin-117m Stannic diethylenetriaminepentaacetic acid: a phase I/II clinical study. Clin Cancer Res 1998; 4: 61-8
14. Bouchet LG, Bolch WE, Goddu SM, et al. Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. J Nucl Med 2000; 41: 682-7
15. Bodei L, Lam M, Chiesa C, et al. EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging 2008; 35: 1934-40
16. Mulford D, Scheinberg D, Jurcic J. The promise of targeted a-particle therapy. J Nucl Med 2005; 46: 199S-204S
17. Tiepolt C, Gruning T, Franke WG. Renaissance of 224 Ra for the treatment of ankylosing spondylitis: clinical experiences. Nucl Med Commun 2002; 23: 61-6
18. Nilsson S, Strang P, Aksnes AK, et al A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 2012; 48: 678-86
19. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-23
20. Henriksen G, Breistol K, Bruland OS, et al. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223) Ra demonstrated in an experimental skeletal metastases model. Cancer Res 2002; 62: 3120-5
21. McDevitt MR, Sgouros G, Finn RD. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 1998; 25: 1341-51
22. Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res 2006; 12: 6250s-7s
23. Henriksen G, Fisher DR, Roeske JC, et al. Targeting of osseous sites with alpha-emitting 223 Ra.comparison with the beta-emitter 89Sr in mice. J Nucl Med 2003; 44: 252-9
24. Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med 2005; 46(Suppl 1): 38S-47S
25. Dornish M, Heier-Baardson H, Petterson EO. Cellular effects of alpha particle radiation from radium-223: ALPHARADIN, a new radiopharmaceutical for the treatment of skeletal metastases. Proc Am Assoc Canc Res (AACR) 2008; 49
26. Nilsson S, Franzen L, Parker C, et al. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin Genitourin Cancer 2013; 11: 20-6
27. Nilsson S, et al. 1.5-year post-Treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA study. J Clin Oncol 2014; 32(Suppl 4): Abstract 9
28. Nilsson S, Larsen RH, Fossa SD, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005; 11: 4451-9
29. Nilsson S BL, Fosså SD, Westling JE, et al. Phase I study of alpharaldin- (223Ra), an a-emitting bone-seeking agent in cancer patients with skeletal metastases. Eur J Nucl Med Mol Imaging 2004; 31
30. Nilsson S, Franzen L, Parker C, et al. Bone-Targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007; 8: 587-94
31. Parker CC, Pascoe S, Chodacki A, et al A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol 2013; 63: 189-97
32. Parker C, Coleman R, Nilsson S, et al. Update survival, quality of life (QOL), and safety data of Radium-223 chloride (223Ra) in patients with castration-resistant prostate cancer (CRPC) with bone metastases from the phase 3 double-blind, randomized, multinational study (ALSYMPCA). ESMO 2012; Oct 2: poster 898 Annals of Oncology supp 2012
33. Sartor O, Coleman R, Nilsson S, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 2014; 15(7): 738-46
34. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-54
35. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005
36. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-97
37. Oudard S, de Bono J, Ozguroglu M, et al. Impact of cabazitaxel (Cbz) + prednisone (P; CbzP) on overall survival (OS) at 2 yrs and in patients (pts) with aggressive disease: post-hoc analyses of TROPIC trial. Presented at European Society for Medical Oncology; 28 September-2 October 2012; Vienna, Austria
38. Goodman OB Jr, Flaig TW, Molina A, et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2014; 17: 34-9
39. Vollmer RT, Dawson NA, Vogelzang NJ. The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate. Cancer 1998; 83: 1989-94
40. Armstrong AJ, Eisenberger MA, Halabi S, et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol 2012; 61: 549-59
41. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23: 4925-35
42. Jung K, Miller K, Wirth M, et al. Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid. Eur Urol 2011; 59: 604-12
43. Even-Sapir E, Metser U, Mishani E, et al. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single-And multifield-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006; 47(2): 287-97
44. Cook G Jr, Parker C, Chua S, et al. 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin). EJNMMI research 2011; 1: 4
45. Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases [Internet]. 2012. Available from: http://clinicaltrials.gov/show/NCT01516762
46. Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases. [Internet]. 2012. Available from: http://clinicaltrials.gov/show/NCT01618370
47. A Study of Alpharadin- With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC). [Internet]. 2010. Available from: http://clinicaltrials.gov/show/NCT01106352
48. Smith M, Parker C, Tombal B, et al. ERA 223-A phase 3 trial of radium-223 dichloride (Ra-223) in combination with abiraterone acetate (AA) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with bone-predominant metastatic castration-resistant. Ann Oncol 2014; 25(Suppl 4): iv278
49. Phase III Radium 223 mCRPC-PEACE III. Available from: http://clinicaltrials.gov/show/NCT02194842